InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates

Group 1: Financial Performance - InspireMD, Inc. reported a quarterly loss of $0.22 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.17, and compared to a loss of $0.21 per share a year ago, indicating an earnings surprise of -29.41% [1] - The company posted revenues of $1.53 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 9.21%, and showing a slight increase from year-ago revenues of $1.51 million [2] - Over the last four quarters, InspireMD has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - InspireMD shares have declined approximately 1.1% since the beginning of the year, while the S&P 500 has seen a decline of -3.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.18 on revenues of $1.93 million, and for the current fiscal year, it is -$0.79 on revenues of $8.22 million [7] - The estimate revisions trend for InspireMD is mixed, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] Group 3: Industry Context - The Medical - Instruments industry, to which InspireMD belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]